272BIO

Beeches Farm Road Maple Barn /
TN22 5QD Uckfield
GB
272BIO
Foundation date
19/07/2019
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Drug delivery
- #Therapeutics - Proteins
- #Therapeutics - Anti-infectives
- #Therapeutics - Antibodies
Therapeutic areas
- #Digestive system
- #Endocrine - nutritional and metabolic diseases
- #Infectious and parasitic diseases
- #Respiratory system
- #Skin and subcutaneous tissue
272BIO are developing biotherapeutics, using innovative technologies, for livestock and companion animal disorders. Applying novel technologies, we are able to reduce hitherto prohibitive production costs and produce affordable therapies. VHH antibodies enable 272BIO to design bespoke drugs for optimal disease control.
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
3011 '23
The GxP Academy: Aseptische Training en werken in LAF/Biosafety Cabinet
Event by: Advipro
Latest news
More news-
argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia
20 hours ago
Read more
-
Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
Wednesday November 22nd 2023
Read more
-
argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis
Thursday November 16th 2023
Read more
Jobs
More jobs-
-
-
27/11/23
Antwerp, Brussels, East Flanders, Hainaut, Liège, Limburg, Luxembourg, Namur, Flemish Brabant, Walloon Brabant, West Flanders, Remote
Project Manager Life Science & IVD
Permanent
Thema Group Belgium
More info?
Ellen Telleir
Communication Coordinator